AI-generated · cited to primary sources · not investment advice
Johnson & Johnson Common Stock (JNJ) Dec 2025 Filing Analysis
What could break the thesis?
The risk is intensifying as the company initiated a new restructuring program for the Surgery franchise in 2025 with estimated total costs of $0.9 - $1.0 billion. (1 intensifying)
“The pre-tax restructuring expense was $205 million in the fiscal year 2025... The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be substantially completed by the end of fiscal year 2026.”
The risk is easing as the company reversed approximately $7.0 billion of its talc reserve following a bankruptcy court dismissal, though it still maintains a $3.4 billion reserve and faces ongoing litigation in the tort system. (1 easing)
“In March 2025, the Texas Bankruptcy Court issued an order dismissing the case (the Texas dismissal) and, as a result, the Company reversed substantially all, or approximately $7 billion, from amounts previously reserved for the bankruptcy resolution. As of the fourth quarter 2025, the total present value of the reserve is approximately $3.4 billion”
See the full cited Risk analysis of Johnson & Johnson Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.